Report cover image

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth (Status and Outlook) 2025-2031

Publisher LP Information, Inc.
Published Sep 05, 2025
Length 112 Pages
SKU # LPI20370820

Description

According to this study, the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size will reach US$ million by 2031.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune motor sensory peripheral neuropathy with chronic demyelination of the proximal peripheral nerves as the main lesion. It belongs to chronic acquired demyelinating multiple neuropathy (ADP), the most common type of CADP, and presents a course of chronic progression or remission - recurrence.

United States market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) players cover Teijin Pharma, Shire, Pfizer, Octapharma, Momenta Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry Forecast” looks at past sales and reviews total world Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) sales in 2024, providing a comprehensive analysis by region and market sector of projected Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) sales for 2025 through 2031. With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) industry.

This Insight Report provides a comprehensive analysis of the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

This report presents a comprehensive overview, market shares, and growth opportunities of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Corticosteroid Therapy
IVIG Treatment
Plasma Exchange Therapy
Immunosuppressive Drug Therapy
Immunomodulator Therapy
Other

Segmentation by Application:
Hospital
Specialist Neurology Clinic
Research and Academic Laboratories

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teijin Pharma
Shire
Pfizer
Octapharma
Momenta Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation
Kedrion
Grifols
CSL Behring (CSL Limited)
Bio Products Laboratory
Baxter
MedDay Pharmaceuticals
GeNeuro Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

112 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Player
4 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast
11 Key Players Analysis
12 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us